Skip to main content
Fig. 7 | BMC Cancer

Fig. 7

From: Regulation of cisplatin-resistant head and neck squamous cell carcinoma by the SRC/ETS-1 signaling pathway

Fig. 7

Inhibition of cisplatin-resistant HNSCC by SRC inhibitor, Dasatinib. a. Cells were treated with increasing doses of Dasatinib for 72 h and IC50 values were determined. b and c. Cal27CP cells were treated with DMSO control or 200 nM Dasatinib and cell migration (b) and invasion (c) were monitored by the xCELLigence real-time cell system. Note: SFM: serum-free media

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us